Jennifer Doudna

Indeed, yes.

And we were, again, fortunate with timing because you mentioned briefly that the IGI had set up a program with the Danaher Corporation back in January of last year.

We call it our Beacon Project, and it's focused on rare disease.

And it's a really interesting, kind of a unique partnership because Danaher is a manufacturing company.

So they have companies that make molecules.

They make proteins.

They make RNA molecules.

They make delivery molecules.

And so they were excited to be involved with us because they want to be a provider of these types of therapies in the future.

And they can see the future of CRISPR is very exciting.

It's an expanding, growing area.

And so that agreement was in place already when the baby KJ case came to our attention.

And so what we're hoping to do with Danaher is, again, work with them and their scientists to continue to ask how can we reduce the cost of these therapies by reducing the cost of the molecules that are necessary, how to make them efficiently.

We already, it's very interesting, Fyodor Urnov has toured their plant in North Dakota recently.

And he found, you know, in talking to their engineers, there are a number of things that we can already see will be possible to do that are going to make the process of manufacturing these molecules faster and cheaper by a lot.

And so it's a win-win for everybody.

And so we're really excited to do that in the context of this new center.

Couldn't agree more.

It's a really interesting moment.

I think what we hope we are is we're at sort of an inflection point where, as I mentioned earlier, all the pieces are in place to do this kind of therapeutic.